[{"id":"da-target-ache","kind":"target","name":"Acetylcholinesterase","aka":[],"tldr":"Blocking this enzyme is how donepezil, rivastigmine, and galantamine try to support signalling.","summary":"The approach is symptomatic. It does not clear plaques or tangles.","asOf":"2026-09-21","links":[{"label":"NICE NG97","url":"https://www.nice.org.uk/guidance/ng97"}],"tags":["dementia-atlas"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["da-donepezil","da-rivastigmine","da-galantamine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"ACHE","biology":"Enzyme that breaks down acetylcholine in the synaptic cleft.","whereFound":[],"targetClass":"enzyme","prevalence":[]},{"id":"da-target-alpha-synuclein","kind":"target","name":"Alpha-synuclein","aka":[],"tldr":"Alpha-synuclein is the protein in Lewy bodies. There is no approved treatment that clears it in dementia.","summary":"Disease-modifying synuclein programmes are research, not standard care.","asOf":"2026-09-21","links":[{"label":"Alzheimer’s Association: Lewy body","url":"https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/dementia-with-lewy-bodies"}],"tags":["dementia-atlas"],"related":[],"cancers":["dementia-with-lewy-bodies","parkinsons-disease-dementia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"SNCA","biology":"Presynaptic protein that aggregates in Lewy bodies.","whereFound":[],"targetClass":"other","prevalence":[]},{"id":"da-target-amyloid-beta","kind":"target","name":"Amyloid-beta","aka":[],"tldr":"Amyloid-beta is the protein fragment that forms plaques in Alzheimer’s disease. Clearing it is the idea behind several antibodies.","summary":"Plaque reduction is now a measurable drug effect. Whether enough clinical benefit follows, for whom, is the practical question.","asOf":"2026-09-21","links":[{"label":"NIA","url":"https://www.nia.nih.gov/health/alzheimers-and-dementia"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease"],"sections":[],"technologies":[],"targets":[],"drugs":["da-lecanemab","da-donanemab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"APP/Aβ","biology":"Peptides from amyloid precursor protein that aggregate into plaques.","whereFound":["Alzheimer’s disease cortex and vessel walls (CAA)."],"targetClass":"other","prevalence":[]},{"id":"da-target-tau","kind":"target","name":"Tau","aka":[],"tldr":"Tau is the tangle protein. Its spread tracks symptoms more closely than plaques in many studies.","summary":"Tau therapeutics remain investigational. MAPT mutations are a rare genetic FTD cause.","asOf":"2026-09-21","links":[{"label":"NIA","url":"https://www.nia.nih.gov/health/alzheimers-and-dementia"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease","frontotemporal-dementia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"MAPT","biology":"Microtubule-associated protein that forms neurofibrillary tangles when hyperphosphorylated.","whereFound":[],"targetClass":"other","prevalence":[]},{"id":"da-target-tdp43","kind":"target","name":"TDP-43","aka":[],"tldr":"TDP-43 is a protein involved in some frontotemporal and related diseases. It is a research target, not a licensed treatment.","summary":"Pathology helps explain FTD heterogeneity. It does not yet yield an approved medicine.","asOf":"2026-09-21","links":[{"label":"NIA: FTD","url":"https://www.nia.nih.gov/health/alzheimers-and-dementia/frontotemporal-disorders"}],"tags":["dementia-atlas"],"related":[],"cancers":["frontotemporal-dementia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"TARDBP","biology":"RNA-binding protein that mislocalises in some FTD and related diseases.","whereFound":[],"targetClass":"other","prevalence":[]}]